FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W201439009> ?p ?o ?g. }

• W201439009 endingPage "72" @default.
• W201439009 startingPage "467" @default.
• W201439009 abstract "Piroxicam-beta-cyclodextrin (PBC) is the first nonsteroidal anti-inflammatory drug (NSAID), in which the active substance is complexed with the cyclic oligosaccharide cyclodextrin, which acts as an artificial receptor. This complex allows single molecules of the NSAID to be released adjacent to the gastrointestinal mucosa, instead of crystals. Since the piroxicam is immediately bioavailable in this formulation, the onset of action is similar to that of a parenteral drug. Since the time contact with gastric mucosa is reduced, the risk of direct-contact gastric irritation is also reduced. There is good evidence that PBC is beneficial in managing acute non-specific back pain (BP) but sufficient evidence on chronic BP is lacking.Thirty-one eligible patients aged 18-85 years, resistant to previous therapy with different NSAIDs, were treated with PBC 20 mg once daily in a 40-day open-label noncomparative study. The patients experienced chronic BP defined as pain between the occipital region and gluteal fold, lasting for at least 6 weeks but not more than 6 months. Efficacy was assessed by changes in pain intensity, paravertebral tonus, functional impairment and morning stiffness using a 4-point numerical rating scale. Patients also self-assessed nocturnal and diurnal pain using the visual analogue scale. Tolerability was assessed by adverse events and routine laboratory evaluations. Global assessment of efficacy and tolerability by physician and patients was performed at the last visit.Using intention-to-treat analysis, all efficacy assessments demonstrated statistically significant improvements over baseline at each follow-up. 90.3% of the patients evaluated the efficacy of PBC as improved or greatly improved, and investigators rated the treatment as improved or greatly improved in 87.1% of patients. Remission was achieved in 19.3% of the patients. Tolerability was also rated highly, with 83.9% of the patients characterizing PBC treatment as good or very good, and the investigators rated the treatment as good or excellent in 87.1% of the patients. Drug related adverse events were reported in 9.7% of patients and prompted discontinuation of the study medication in 3.2% of patients. No serious adverse events were reported.These results suggest that the newly developed dosage form of piroxicam is effective and well tolerated in the treatment of patients with chronic BP. Thus, PBC, may be an important new treatment option in this condition. (Tab. 3, Fig. 3, Ref. 36.)." @default.
• W201439009 created "2016-06-24" @default.
• W201439009 creator A5013635622 @default.
• W201439009 creator A5014933318 @default.
• W201439009 creator A5041468391 @default.
• W201439009 creator A5048006564 @default.
• W201439009 creator A5050576966 @default.
• W201439009 creator A5083364001 @default.
• W201439009 creator A5083482320 @default.
• W201439009 date "2002-01-01" @default.
• W201439009 modified "2023-10-06" @default.
• W201439009 title "Efficacy and tolerability of piroxicam-beta-cyclodextrin in the outpatient management of chronic back pain." @default.
• W201439009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12696775" @default.
• W201439009 hasPublicationYear "2002" @default.
• W201439009 type Work @default.
• W201439009 sameAs 201439009 @default.
• W201439009 citedByCount "4" @default.
• W201439009 countsByYear W2014390092015 @default.
• W201439009 crossrefType "journal-article" @default.
• W201439009 hasAuthorship W201439009A5013635622 @default.
• W201439009 hasAuthorship W201439009A5014933318 @default.
• W201439009 hasAuthorship W201439009A5041468391 @default.
• W201439009 hasAuthorship W201439009A5048006564 @default.
• W201439009 hasAuthorship W201439009A5050576966 @default.
• W201439009 hasAuthorship W201439009A5083364001 @default.
• W201439009 hasAuthorship W201439009A5083482320 @default.
• W201439009 hasConcept C126322002 @default.
• W201439009 hasConcept C14184104 @default.
• W201439009 hasConcept C142724271 @default.
• W201439009 hasConcept C1862650 @default.
• W201439009 hasConcept C197934379 @default.
• W201439009 hasConcept C204787440 @default.
• W201439009 hasConcept C2778139025 @default.
• W201439009 hasConcept C2778375690 @default.
• W201439009 hasConcept C2781118164 @default.
• W201439009 hasConcept C3020110884 @default.
• W201439009 hasConcept C42219234 @default.
• W201439009 hasConcept C46821324 @default.
• W201439009 hasConcept C71924100 @default.
• W201439009 hasConceptScore W201439009C126322002 @default.
• W201439009 hasConceptScore W201439009C14184104 @default.
• W201439009 hasConceptScore W201439009C142724271 @default.
• W201439009 hasConceptScore W201439009C1862650 @default.
• W201439009 hasConceptScore W201439009C197934379 @default.
• W201439009 hasConceptScore W201439009C204787440 @default.
• W201439009 hasConceptScore W201439009C2778139025 @default.
• W201439009 hasConceptScore W201439009C2778375690 @default.
• W201439009 hasConceptScore W201439009C2781118164 @default.
• W201439009 hasConceptScore W201439009C3020110884 @default.
• W201439009 hasConceptScore W201439009C42219234 @default.
• W201439009 hasConceptScore W201439009C46821324 @default.
• W201439009 hasConceptScore W201439009C71924100 @default.
• W201439009 hasIssue "12" @default.
• W201439009 hasLocation W2014390091 @default.
• W201439009 hasOpenAccess W201439009 @default.
• W201439009 hasPrimaryLocation W2014390091 @default.
• W201439009 hasRelatedWork W126807823 @default.
• W201439009 hasRelatedWork W156026954 @default.
• W201439009 hasRelatedWork W1972528425 @default.
• W201439009 hasRelatedWork W1996644805 @default.
• W201439009 hasRelatedWork W2013238063 @default.
• W201439009 hasRelatedWork W201439009 @default.
• W201439009 hasRelatedWork W2161400122 @default.
• W201439009 hasRelatedWork W2419561648 @default.
• W201439009 hasRelatedWork W3022310051 @default.
• W201439009 hasRelatedWork W2529862827 @default.
• W201439009 hasVolume "103" @default.
• W201439009 isParatext "false" @default.
• W201439009 isRetracted "false" @default.
• W201439009 magId "201439009" @default.
• W201439009 workType "article" @default.